Nakane, K.; Taniguchi, K.; Nezasa, M.; Enomoto, T.; Yamada, T.; Tomioka-Inagawa, R.; Niwa, K.; Tomioka, M.; Ishida, T.; Nagai, S.;
et al. Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan. Cancers 2024, 16, 2648.
https://doi.org/10.3390/cancers16152648
AMA Style
Nakane K, Taniguchi K, Nezasa M, Enomoto T, Yamada T, Tomioka-Inagawa R, Niwa K, Tomioka M, Ishida T, Nagai S,
et al. Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan. Cancers. 2024; 16(15):2648.
https://doi.org/10.3390/cancers16152648
Chicago/Turabian Style
Nakane, Keita, Kazuki Taniguchi, Minori Nezasa, Torai Enomoto, Toyohiro Yamada, Risa Tomioka-Inagawa, Kojiro Niwa, Masayuki Tomioka, Takashi Ishida, Shingo Nagai,
and et al. 2024. "Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan" Cancers 16, no. 15: 2648.
https://doi.org/10.3390/cancers16152648
APA Style
Nakane, K., Taniguchi, K., Nezasa, M., Enomoto, T., Yamada, T., Tomioka-Inagawa, R., Niwa, K., Tomioka, M., Ishida, T., Nagai, S., Yokoi, S., Taniguchi, T., Kawase, M., Kawase, K., Iinuma, K., Tobisawa, Y., & Koie, T.
(2024). Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan. Cancers, 16(15), 2648.
https://doi.org/10.3390/cancers16152648
